Heterocyclic compounds for cancer imaging and treatment and methods for their use

1. A compound having the following structure (I):

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:

X is —O—, —S(O) 0-2 —, —C(═O)—, —C(OR 5 ) 2 —, —C(OR 5 )(OC(═O)R 13 )—, —C(R 8 R 9 )—, —C(═CR 8 R 9 )—, —N(R 9 )—, —N(COR 9 )—, —CHNR 8 R 9 —, —C(═NR 9 )—, —C(═NOR 5 )—, —C(═N—NHR 5 )—;

R 1 and R 2 are each independently H, hydroxyl, —O-heterocyclyl, or —OC(═O)R 13 ;

R 3 is a 4-7 membered heterocyclyl which is optionally substituted with one or more R 6 ;

R 5 is each independently H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

R 6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123 I, hydroxyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 6 -C 12 aryl, wherein each R 6 is optionally substituted with one or more of halogen, 123 I, 18 F, hydroxyl, —OS(O) 2 -aryl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

R 8 is halogen, —S(O) 0-2 R 5 , C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, aryl, aralkyl, C 1 -C 10 acyl, or —NR 5 R 5 ;

R 9 is H, halogen, —S(O) 0-2 R 5 , C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, aryl, aralkyl, C 1 -C 10 acyl, or —NR 5 R 5 ; or

R 8 and R 9 can join to form an unsubstituted or substituted mono-, bi-, or tri-cyclic carbocycle or heterocycle containing from 3 to 20 carbon atoms;

R 11a , R 11b , R 11c and R 11d are each independently H, F, Cl, Br, I, 123 I, hydroxyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —OR 5 , —OC(═O)R 13 , C 1 -C 10 acyl, —S(O) 0-2 R 5 , —NO 2 , —CN, —NH 2 , —NHR 5 , or —N(R 5 ) 2 ;

R 13 is each independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

n 1 and n 2 are each independently 0, 1, or 2; and

n 3 is 0, 1, 2, 3, 4, or 5.

2. The compound of claim 1 , wherein X is —C(R 8 R 9 )—.

3. The compound of claim 1 , wherein R 8 and R 9 are C 1 -C 10 alkyl.

4. The compound of claim 1 , wherein R 8 and R 9 are methyl.

5. The compound of claim 1 , wherein R 3 is 5-7 membered heterocylyl, wherein said heterocyclyl comprises at least one N atom in the ring.

6. The compound of claim 1 , wherein R 3 is selected from a group consisting of oxazine, azepine, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, dioxane, morpholine, dithiane, thiomorpholine, piperazine, and tetrazine.

7. The compound of claim 1 , wherein each R 13 is independently methyl, ethyl or propyl.

8. The compound of claim 1 , wherein each R 13 is methyl.

9. The compound of claim 1 , wherein at least one of R 11a , R 11b , R 11c and R 11d is Cl, Br, I or 123 I.

10. The compound of claim 1 , wherein at least one of R 11a , R 11b , R 11c , and R 11d is I; and at least one of R 11a , R 11b , R 11c and R 11d is 123 I.

11. The compound of claim 1 , wherein n 3 is 0, 1, or 2.

12. The compound of claim 1 , wherein the compound has one of the following structures:

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

13. The compound of claim 1 , wherein the compound has one of the following structures:

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

14. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of formula (I):

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:

X is —O—, —S(O) 0-2 —, —C(═O)—, —C(OR 5 ) 2 —, —C(OR 5 )(OC(═O)R 13 )—, —C(R 8 R 9 )—, —C(═CR 8 R 9 )—, —N(R 9 )—, —N(COR 9 )—, —CHNR 8 R 9 —, —C(═NR 9 )—, —C(═NOR 5 )—, —C(═N—NHR 5 )—;

R 1 and R 2 are each independently H, hydroxyl, —O-heterocyclyl, or —OC(═O)R 13 ;

R 3 is a 4-7 membered heterocyclyl which is optionally substituted with one or more R 6 ;

R 5 is each independently H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

R 6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123 I, hydroxyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 6 -C 12 aryl, wherein each R 6 is optionally substituted with one or more of halogen, 123 I, 18 F, hydroxyl, —OS(O) 2 -aryl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

R 8 is halogen, —S(O) 0-2 R 5 , C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, aryl, aralkyl, C 1 -C 10 acyl, or —NR 5 R 5 ;

R 9 is H, halogen, —S(O) 0-2 R 5 , C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, aryl, aralkyl, C 1 -C 10 acyl, or —NR 5 R 5 ; or

R 8 and R 9 can join to form an unsubstituted or substituted mono-, bi-, or tri-cyclic carbocycle or heterocycle containing from 3 to 20 carbon atoms;

R 11a , R 11b , R 11c and R 11d are each independently H, F, Cl, Br, I, 123 I, hydroxyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —OR 5 , —OC(═O)R 13 , C 1 -C 10 acyl, —S(O) 0-2 R 5 , —NO 2 , —CN, —NH 2 , —NHR 5 , or —N(R 5 ) 2 ;

R 13 is each independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

n 1 and n 2 are each independently 0, 1, or 2; and

n 3 is 0, 1, 2, 3, 4, or 5.

15. The pharmaceutical composition of claim 14 , further comprising an additional therapeutic agent.

16. The pharmaceutical composition of claim 15 , wherein the additional therapeutic agent is for treating prostate cancer, breast cancer, ovarian cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration.

17. The pharmaceutical composition of claim 15 , wherein the additional therapeutic agent is enzalutamide, Galeterone, ARN-509, abiraterone, bicalutamide, nilutamide, flutamide, cyproterone acetate, docetaxel, Bevacizumab (Avastin), OSU-HDAC42, VITAXIN, sunitumib, ZD-4054, Cabazitaxel (XRP-6258), MDX-010 (Ipilimumab), OGX 427, OGX 011, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105,111, ODM-201, or radium 233.

18. A method for modulating androgen receptor activity, comprising: administering a pharmaceutical composition according to claim 14 to a patient in need thereof.

19. A method for treating a condition or disease that is responsive to modulation of androgen receptor activity, comprising: administering a pharmaceutical composition according to claim 14 to a patient in need thereof,

wherein said condition or disease is selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age-related macular degeneration.

20. The method of claim 19 , wherein the condition or disease is prostate cancer.

21. The method of claim 19 , wherein the condition or disease is castration resistant prostate cancer.

22. The method of claim 19 , wherein the condition or disease is androgen-dependent prostate cancer.

23. A method for treating a condition or disease selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age-related macular degeneration, comprising:

administering to a patient in need thereof a compound having the following structure (I):

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:

X is —O—, —S(O) 0-2 —, —C(═O)—, —C(OR 5 ) 2 —, —C(OR 5 )(OC(═O)R 13 )—, —C(R 8 R 9 )—, —C(═CR 8 R 9 )—, —N(R 9 )—, —N(COR 9 )—, —CHNR 8 R 9 —, —C(═NR 9 )—, —C(═NOR 5 )—, —C(═N—NHR 5 )—;

R 1 and R 2 are each independently H, hydroxyl, —O-heterocyclyl, or —OC(═O)R 13 ;

R 3 is a 4-7 membered heterocyclyl which is optionally substituted with one or more R 6 ;

R 5 is each independently H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

R 6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123 I, hydroxyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 6 -C 12 aryl, wherein each R 6 is optionally substituted with one or more of halogen, 123 I, 18 F, hydroxyl, —OS(O) 2 -aryl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

R 8 is halogen, —S(O) 0-2 R 5 , C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, aryl, aralkyl, C 1 -C 10 acyl, or —NR 5 R 5 ;

R 9 is H, halogen, —S(O) 0-2 R 5 , C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, aryl, aralkyl, C 1 -C 10 acyl, or —NR 5 R 5 ; or

R 8 and R 9 can join to form an unsubstituted or substituted mono-, bi-, or tri-cyclic carbocycle or heterocycle containing from 3 to 20 carbon atoms;

R 11a , R 11b , R 11c and R 11d are each independently H, F, Cl, Br, I, 123 I, hydroxyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —OR 5 , —OC(═O)R 13 , C 1 -C 10 acyl, —S(O) 0-2 R 5 , —NO 2 , —CN, —NH 2 , —NHR 5 , or —N(R 5 ) 2 ;

R 13 is each independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;

n 1 and n 2 are each independently 0, 1, or 2; and

n 3 is 0, 1, 2, 3, 4, or 5.

24. The method of claim 23 , wherein the condition or disease is prostate cancer.

25. The method of claim 23 , wherein the condition or disease is castration resistant prostate cancer or androgen-dependent prostate cancer.

26. A method of imaging cancer, the method comprising administering a compound of claim 1 to a subject and detecting the presence or absence of cancer by use of SPECT or PET.

27. The method of claim 26 , wherein the method identifies the presence or absence of a tumor.

28. The method of claim 26 , wherein the method identifies the location of a tumor.

29. The method of claim 26 , wherein the cancer is prostate cancer.

30. The method of claim 26 , wherein the compound of claim 1 is selected from:

or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

31. A method of imaging cancer, the method comprising administering the pharmaceutical composition of claim 14 to a subject and detecting the presence or absence of cancer by use of SPECT or PET.